Landscape of the Japanese Regulations on Regenerative Medicines

Dr Yuki Sato, Head, Division of Cell-Based Therapeutic Products from National Institute of Health Sciences gave a presentation on the latest landscape of the Japanese regulations on regenerative medicines. 

The presentation explains the differences between the two relevant Acts:

  1. Regenerative Medicine Safety Act for medical practices using processed cells
  2. Pharmaceuticals and Medical Devices Act.  

The presentation material is available here.

This was a part of a webinar session co-organised by DIT Japan, Cell & Gene Therapy Catapult and Kanagawa Prefecture in November 2020 to raise awareness of the UK’s Advanced therapy ecosystem and share the latest technological development and regulations.